Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Citi
Cerilliant
Federal Trade Commission
QuintilesIMS
Express Scripts
Boehringer Ingelheim
Merck
Baxter

Generated: July 19, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR HEPARIN SODIUM

« Back to Dashboard

Clinical Trials for HEPARIN SODIUM

Trial ID Title Status Sponsor Phase Summary
NCT00000468 Myocardial Infarction Triage and Intervention Project (MITI) Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 To determine the practicality, benefit, and safety of paramedic administration of thrombolytic therapy for acute myocardial infarction. The feasibility of paramedics correctly identifying candidates for thrombolytic therapy following myocardial infarction was assessed in Phase I. In Phase II, pre-hospital thrombolytic therapy was compared with in-hospital thrombolytic therapy.
NCT00000468 Myocardial Infarction Triage and Intervention Project (MITI) Completed University of Washington Phase 3 To determine the practicality, benefit, and safety of paramedic administration of thrombolytic therapy for acute myocardial infarction. The feasibility of paramedics correctly identifying candidates for thrombolytic therapy following myocardial infarction was assessed in Phase I. In Phase II, pre-hospital thrombolytic therapy was compared with in-hospital thrombolytic therapy.
NCT00182143 PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT) Completed Australian and New Zealand Intensive Care Society Clinical Trials Group Phase 3 The purpose of this study is to evaluate the effect of Low Molecular Weight Heparin (LMWH) (Fragmin, dalteparin) versus Unfractionated Heparin (UFH) on the primary outcome of proximal leg Deep Vein Thrombosis (DVT) diagnosed by compression ultrasound, and the secondary outcomes of Pulmonary Embolism (PE), bleeding, Heparin-Induced Thrombocytopenia (HIT), and objectively confirmed venous thrombosis at any site.
NCT00182143 PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT) Completed Canadian Critical Care Trials Group Phase 3 The purpose of this study is to evaluate the effect of Low Molecular Weight Heparin (LMWH) (Fragmin, dalteparin) versus Unfractionated Heparin (UFH) on the primary outcome of proximal leg Deep Vein Thrombosis (DVT) diagnosed by compression ultrasound, and the secondary outcomes of Pulmonary Embolism (PE), bleeding, Heparin-Induced Thrombocytopenia (HIT), and objectively confirmed venous thrombosis at any site.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Clinical Trial Conditions for HEPARIN SODIUM

Condition Name

Condition Name for HEPARIN SODIUM
Intervention Trials
Myocardial Infarction 4
Thrombosis 4
Healthy 3
Obesity 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for HEPARIN SODIUM
Intervention Trials
Thrombosis 9
Venous Thrombosis 7
Thromboembolism 5
Myocardial Infarction 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for HEPARIN SODIUM

Trials by Country

Trials by Country for HEPARIN SODIUM
Location Trials
United States 38
Canada 14
Germany 11
Spain 10
Italy 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for HEPARIN SODIUM
Location Trials
New York 5
Texas 5
California 5
Ohio 3
Kansas 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for HEPARIN SODIUM

Clinical Trial Phase

Clinical Trial Phase for HEPARIN SODIUM
Clinical Trial Phase Trials
Phase 4 19
Phase 3 11
Phase 2/Phase 3 3
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for HEPARIN SODIUM
Clinical Trial Phase Trials
Completed 29
Recruiting 8
Unknown status 8
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for HEPARIN SODIUM

Sponsor Name

Sponsor Name for HEPARIN SODIUM
Sponsor Trials
Azidus Brasil 4
GlaxoSmithKline 4
Canadian Institutes of Health Research (CIHR) 3
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for HEPARIN SODIUM
Sponsor Trials
Other 79
Industry 28
NIH 5
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Teva
Daiichi Sankyo
US Army
Fish and Richardson
Queensland Health
Chubb
Argus Health
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.